glp-1 news today insurers coverage Agonists Market Report 2025-2033, By Product, Molecule, and Geo Paving the way for expanded
Description
PMCID: PMC5286837
Boehringer Ingelheim / Zealand Pharma (ZLDPF): Survodutide (aka BI 456906) [44] [44] In a placebo-controlled study evaluating the GLP1R/GR dual agonist (Obesity Indication), patients received weekly subcutaneous injections of 4.8mg for a duration of 46 weeks
Pulse & Remedy claims peptide therapy "is considered safe for extended use" without citing a study behind that statement, underscoring the regulatory gap between non-prescription peptides and FDA-approved GLP-1 drugs
Over time, EtO exposure may weaken the immune system, increasing susceptibility to infections and other serious health conditions
